

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL 2724
16-MD-2724**

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFÉ

ALL ACTIONS

**PRETRIAL ORDER NO. 67
(SCHEDULING ORAL ARGUMENT)**

AND NOW, this 20th day of December 2018, the Court having reviewed Defendants' Motion for Order Limiting Extrajudicial Statements and for Compliance with this Court's Order and the Supplement thereto [MDL Doc. Nos. 805 and 806], it is hereby **ORDERED** that the Court will hear oral argument on the Motion following the previously-scheduled Leadership Status Conference on **January 4, 2019**. In accordance with the Local Rules of Civil Procedure, responses to the Motion shall be filed no later than **January 2, 2019**. The Court will not rule until the Motion is fully briefed, but notes that the Court's Orders remain in effect, including Pretrial Order No. 50.¹

It is so **ORDERED**.

BY THE COURT:

/s/ Cynthia M. Rufe

CYNTHIA M. RUFÉ, J.

¹ The Motion was filed the evening of December 18, 2018. On December 14, 2018, attorneys Chul Pak (counsel for Mylan), Benjamin Holt (counsel for Mylan), Sheron Korpus (counsel for Actavis and Teva), and W. Joseph Nielsen (counsel for the Connecticut Attorney General) called Chambers and spoke with the Court's law clerk. Counsel stated that a reporter had been in contact with Mylan the night before and was preparing an article based in part on an unredacted copy of the State Plaintiffs' Amended Complaint, which the reporter had obtained from a source unknown to counsel. Counsel stated that they called to alert the Court to this development and did not request that the Court take any action at that time.